Table 1. Baseline characteristics.
| Characteristics | ≥1 minor PI mutation | No minor PI mutation | P * |
| Sex | .227 | ||
| Male | 640 (82.9%) | 342 (80.1%) | |
| Female | 132 (17.1%) | 85 (19.9%) | |
| Ethnicity | .149 | ||
| White | 701 (90.8%) | 398 (93.2%) | |
| Other | 71 (9.2%) | 29 (6.8%) | |
| Transmission category | .020 | ||
| Men who have sex with men | 426 (55.2%) | 213 (49.9%) | |
| Heterosexual | 187 (24.2%) | 111 (26.0%) | |
| Intravenous drug use | 129 (16.7%) | 95 (22.3%) | |
| Other | 30 (3.9%) | 8 (1.9%) | |
| Median [IQR] age | 45 [39–51] | 45 [39–51] | .984 |
| HIV-1 RNA | .263 | ||
| <10,000 copies/mL | 133 (17.2%) | 70 (16.4%) | |
| 10,000–99,999 copies/mL | 278 (36.0%) | 174 (40.8%) | |
| >100000 copies/mL | 361 (46.8%) | 183 (42.9%) | |
| Median [IQR] log10 HIV-1 RNA | 4.9 [4.4–5.5] | 4.9 [4.3–5.4] | .315 |
| CD4 cell count | .024 | ||
| <200 cells/µL | 334 (43.3%) | 156 (36.5%) | |
| 200–300 cells/µL | 253 (32.8%) | 141 (33.0%) | |
| >350 cells/µL | 185 (24.0%) | 130 (30.4%) | |
| Median (IQR) CD4 cells/µL | 223 [125.5–339.5] | 255 [141–379] | .010 |
| CDC stage C | 137 (17.8%) | 65 (15.2%) | .264 |
| NRTI mutation | 33 (4.3%) | 12 (2.8%) | .201 |
| Administered PIs | <.001 | ||
| unboosted PIs | 136 (17.6%) | 119 (27.9%) | |
| boosted PIs | 636 (82.4%) | 308 (72.1%) | |
| Specific PI | <.001 | ||
| Nelfinavir | 115 (14.9%) | 105 (24.6%) | |
| Other unboosted PIs | 21 (2.7%) | 14 (3.3%) | |
| Lopinavir | 415 (53.8%) | 175 (41.0%) | |
| Atazanavir/r | 193 (25.0%) | 53 (12.4%) | |
| Indinavir/r | 23 (3.0%) | 20 (4.7%) | |
| Other boosted PIs | 5 (0.7%) | 60 (14.1%) | |
| Median [IQR] year of ART start | 2006 [2003–2008] | 2005 [2001–2008] | .005 |
P* Fishers exact p value for categorical variable and Wilcoxon rank sum for continuous variables.
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile range; NRTI nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.